IsoRay moves Proxcelan plant to WA:
This article was originally published in Clinica
Manufacturer of Proxcelan brachytherapy seeds IsoRay Medical is set to move production to a new facility in Richland, Washington. The new plant, which will house the company's radioactive and non-radioactive facilities, brings IsoRay's operations to a single location. Production of the company's primary product will be doubled and the company will undergo the development of isotopes for new cancer treatments. Proxcelan is the brand name for cesium-131 seeds designed to treat prostate cancer via low dose radiation. Although the technology has solely been used to treat prostate cancer, it received FDA clearance for the treatment of all malignancies in March 2003.